NCT00847080

Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism

Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.

Detailed description

Symptomatic reactive hypoglycemia is an abnormal glucose decrease after meal ingestion. Patients with this abnormality as an early manifestation of glucose intolerance are at higher risk of type 2 diabetes. The pathophysiology of this abnormality appears to be related with delayed first phase insulin release. Improvement of first phase insulin secretion and delay in gastric emptying induced by sitagliptin phosphate could have favorable effects in patients in whom delayed insulin secretion is associated with reactive hypoglycemia.

Conditions

• Reactive Hypoglycemia

Interventions

Type	Name	Description
DRUG	Sitagliptin phosphate	Sitagliptin phosphate 100 mg per day per 2 weeks
DRUG	Placebo	Placebo 1 tablet per day per 2 weeks

Timeline

• Start date: 2008-12-01
• Primary completion: 2010-12-01
• Completion: 2011-03-01
• First posted: 2009-02-19
• Last updated: 2011-04-26

Locations

1 site across 1 country: Mexico